Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$15.38 USD
-0.07 (-0.45%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $15.40 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TEVA 15.38 -0.07(-0.45%)
Will TEVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Other News for TEVA
Teva management to meet with Truist
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Highlights: Strong Growth in ...
Teva Pharmaceuticals (TEVA) Reports Continued Growth in Q2 2025
Truist Hosts Influential Meeting on July 30-31 with Focus on TEVA